Hsbc Holdings PLC Apellis Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 118,487 shares of APLS stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

118,487

Previous 34,924 239.27%

Holding current value

$3.93 Million

Previous $1.34 Million 155.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $2.41 Million - $3.44 Million	83,563 Added 239.27%	118,487 $3.42 Million
Q2 2024 Aug 12, 2024	SELL	$38.07 - $59.71 $2.42 Million - $3.8 Million	-63,626 Reduced 64.56%	34,924 $1.34 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $5.46 Million - $7.14 Million	98,550 New	98,550 $5.79 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.2 Million - $4.51 Million	50,544 New	50,544 $1.92 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $816,722 - $1.17 Million	17,530 New	17,530 $1.16 Million
Q2 2022 Aug 11, 2022	BUY	$35.07 - $59.21 $34,929 - $58,973	996 Added 10.07%	10,887 $497,000
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $187,583 - $286,294	5,290 Added 114.98%	9,891 $504,000
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $141,434 - $226,185	4,601 New	4,601 $217,000
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $116,211 - $258,477	-3,701 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $151,370 - $240,194	3,701 New	3,701 $233,000
Q3 2020 Nov 12, 2020	SELL	$25.89 - $33.65 $196,246 - $255,067	-7,580 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $187,984 - $291,754	7,580 New	7,580 $248,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Apellis Pharmaceuticals, Inc. Transaction History